Halting GLP-1 Treatment May Undo Crucial Health Benefits, Study Warns
Stopping popular GLP-1 weight loss and diabetes medications, even for a short period, can rapidly diminish their significant benefits for cardiovascular health. New research indicates that discontinuing these treatments, which are widely used by millions, can lead to a concerning resurgence of health risks.
A comprehensive three-year study conducted by Washington University in St. Louis, involving over 333,000 U.S. veterans diagnosed with type 2 diabetes who were prescribed GLP-1 medications, has revealed a strong correlation between halting or interrupting treatment and a notable increase in the risk of major cardiovascular events.
The findings are particularly stark: after just two years off GLP-1 drugs, patients experienced a 22 percent higher risk of experiencing a heart attack, stroke, or even death. This builds upon existing research that has already demonstrated that discontinuing these medications can reverse weight loss, and can also negatively impact inflammation levels and blood pressure, both critical factors in cardiovascular health.
Dr. Ziyad Al-Aly, a clinical epidemiologist at the university and the senior author of the study, highlighted the disparity between the enthusiasm for starting these medications and the lack of attention paid to the consequences of stopping them. “There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop,” Dr. Al-Aly stated.
He elaborated on the reasons for discontinuation, noting that many individuals cease treatment due to cost, unpleasant side effects, or supply shortages. “When they stop, it’s not just weight that comes back; they experience a resurgence in inflammation, blood pressure and cholesterol. Weight regain is visible; the metabolic reversal is not,” he explained.
The research methodology involved comparing the health outcomes of 132,551 participants who were prescribed GLP-1s for their type 2 diabetes with those of 201,136 participants who were on a different diabetes treatment, sulfonylureas. The health of all participants was monitored every six months. The study observed that more than a quarter of the GLP-1 group stopped taking their medication, while 23 percent experienced an interruption of six months or more.
Conversely, participants who adhered to their GLP-1 medication regimen consistently for the entire three-year study period demonstrated an 18 percent reduced risk of life-threatening cardiovascular events. Even for individuals who discontinued treatment after two to two-and-a-half years, a slightly reduced benefit was still observed. However, for those who stopped taking GLP-1s for a full year, the risk of cardiovascular events increased by 14 percent.
“Our data suggest this metabolic whiplash is detrimental to heart health,” Dr. Al-Aly emphasised. “Restarting the medication helped restore some protection, but only partially, showing that discontinuation leaves a lasting scar.”
The Growing Use and Challenges of GLP-1 Medications
GLP-1 receptor agonists, including popular brands like semaglutide-based Ozempic and Wegovy, and tirzepatide-based Mounjaro and Zepbound, are now used by a significant portion of the adult population in the United States, with approximately one in eight adults reportedly using these medications.
However, a substantial number of users, estimated to be around half, discontinue GLP-1s relatively soon after starting treatment. This trend is attributed to several factors, including the considerable cost of the medications, the occurrence of uncomfortable side effects, and individual age-related considerations.
In response to these access and affordability concerns, drug manufacturers are reportedly working to make their products more accessible and cost-effective. Novo Nordisk, the pharmaceutical company behind Ozempic and Wegovy, has publicly announced plans to implement significant price reductions, potentially slashing costs by up to 50 percent.
Experts in the field express concern over the high rate of discontinuation, stressing that these medications are not intended as a short-term fix. Reimar Thomsen, a professor at Denmark’s Aarhus University, commented that the medications require long-term adherence to be effective. “For them to work effectively, they need to be taken long-term. All of the beneficial effects on appetite control are lost if the medication is stopped,” Professor Thomsen stated.
The ongoing research into GLP-1 medications and their long-term impact underscores the importance of sustained treatment for managing chronic conditions like type 2 diabetes and achieving lasting health improvements. The findings serve as a crucial reminder for both patients and healthcare providers to consider the full lifecycle of treatment, including the potential ramifications of discontinuing these powerful medications.
